Defining acceptable limits for the metrological traceability of specific measurands

被引:36
作者
Bais, Renze [1 ]
Armbruster, Dave [2 ]
Jansen, Rob T. P. [3 ]
Klee, George [4 ]
Panteghini, Mauro [5 ]
Passarelli, Joseph [6 ]
Sikaris, Ken A.
机构
[1] Rbaisconsulting Com, Sydney, NSW, Australia
[2] Abbott Diagnost, Abbott Pk, IL 60064 USA
[3] SKML, Nijmegen, Netherlands
[4] Mayo Clin, Rochester, MN 55905 USA
[5] Univ Milan, Ctr Metrol Traceabil Lab Med CIRME, Milan, Italy
[6] Roche Diagnost GmbH, D-82377 Penzberg, Germany
关键词
IFCC; metrological traceability; result equivalence; standardization; STANDARDIZATION; MANUFACTURERS; VARIABILITY; INFORMATION; CRITERIA; GOALS;
D O I
10.1515/cclm-2013-0122
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Although manufacturers are compelled by the European IVD Directive, 98/79/EC, to have traceability of the values assigned to their calibrators if suitable higher order reference materials and/or procedures are available, there is still no equivalence of results for many measurands determined in clinical laboratories. The adoption of assays with metrological traceable results will have a significant impact on laboratory medicine in that results will be equivalent across different laboratories and different analytical platforms. The IFCC WG on Allowable Errors for Traceable Results has been formed to define acceptable limits for metrological traceability chains for specific measurands in order to promote the equivalence of patient results. These limits are being developed based on biological variation for the specific measurands. Preliminary investigations have shown that for some measurands, it is possible for manufacturers to assign values to assay calibrators with a measurement uncertainty that allows the laboratory enough combined uncertainty for their routine measurements. However, for other measurands, e. g., plasma sodium, current assays are too imprecise to fulfil limits based on biological variation. Although an alternative approach based on probability theory is being investigated, the most desirable approach would be for industry to improve measurement methods so that they meet clinical requirements.
引用
收藏
页码:973 / 979
页数:7
相关论文
共 28 条
[1]  
[Anonymous], 2003, ISO 17511
[2]  
[Anonymous], 2012, CLSI DOCUMENT C51 A
[3]  
[Anonymous], 2006, IFCC CLSI X5 R
[4]  
[Anonymous], 2010, CLSI C 53A
[5]   Measurement traceability and US IVD manufacturers: the impact of metrology [J].
Armbruster, Dave .
ACCREDITATION AND QUALITY ASSURANCE, 2009, 14 (07) :393-398
[6]  
Armbruster David, 2007, Clin Biochem Rev, V28, P105
[7]   What information should manufacturers provide on their procedures? [J].
Bais, Renze .
CLINICAL CHEMISTRY, 2006, 52 (08) :1624-1625
[8]   Biologic variability of C-reactive protein: Is the available information reliable? [J].
Braga, Federica ;
Panteghini, Mauro .
CLINICA CHIMICA ACTA, 2012, 413 (15-16) :1179-1183
[9]   Biological variability of glycated hemoglobin [J].
Braga, Federica ;
Dolci, Alberto ;
Mosca, Andrea ;
Panteghini, Mauro .
CLINICA CHIMICA ACTA, 2010, 411 (21-22) :1606-1610
[10]   Characterization of a new certified reference material for human Cardiac Troponin I [J].
Bunk, DM ;
Welch, MJ .
CLINICAL CHEMISTRY, 2006, 52 (02) :212-219